Utilizing NCCN Guidelines for Treatment Guidance in EGFR-Mutated NSCLC

Narjust Florez, MD, explains how the National Comprehensive Cancer Network (NCCN) Guidelines inform evidence-based treatment selection in EGFR-mutated advanced non–small cell lung cancer (NSCLC). Florez describes how guideline recommendations integrate clinical trial data, molecular testing results, and line-of-therapy considerations. She underscores the role of guidelines as a framework that must still be adapted to individual patient characteristics and real-world clinical complexity.